Unknown

Dataset Information

0

Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada.


ABSTRACT:

Background

In British Columbia, Canada, most adults 50-69 years old became eligible for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in April 2021, with chimpanzee adenoviral vectored vaccine (ChAdOx1) restricted to ≥55-year-olds and second doses deferred ≥6 weeks to optimize single-dose coverage.

Methods

Among adults 50-69 years old, single-dose messenger RNA (mRNA) and ChAdOx1 vaccine effectiveness (VE) against SARS-CoV-2 infection and hospitalization, including variant-specific, was assessed by test-negative design between 4 April and 2 October 2021.

Results

Single-dose VE included 11 861 cases and 99 544 controls. Median of postvaccination follow-up was 32 days (interquartile range, 15-52 days). Alpha, Gamma, and Delta variants comprised 23%, 18%, and 56%, respectively, of genetically characterized viruses. At 21-55 days postvaccination, single-dose mRNA and ChAdOx1 VE (95% confidence interval [CI]) was 74% (71%-76%) and 59% (53%-65%) against any infection and 86% (80%-90%) and 94% (85%-97%) against hospitalization, respectively. VE (95% CI) was similar against Alpha and Gamma infections for mRNA (80% [76%-84%] and 80% [75%-84%], respectively) and ChAdOx1 (69% [60%-76%] and 66% [56%-73%], respectively). mRNA VE was lower at 63% (95% CI, 56%-69%) against Delta but 85% (95% CI, 71%-92%) against Delta-associated hospitalization (nonestimable for ChAdOx1).

Conclusions

A single mRNA or ChAdOx1 vaccine dose gave important protection against SARS-CoV-2, including early variants of concern. ChAdOx1 VE was lower against infection, but 1 dose of either vaccine reduced the hospitalization risk by >85% to at least 8 weeks postvaccination. Findings inform program options, including longer dosing intervals.

SUBMITTER: Skowronski DM 

PROVIDER: S-EPMC8807316 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada.

Skowronski Danuta M DM   Setayeshgar Solmaz S   Zou Macy M   Prystajecky Natalie N   Tyson John R JR   Sbihi Hind H   Fjell Chris D CD   Galanis Eleni E   Naus Monika M   Patrick David M DM   El Adam Shiraz S   Ahmed May A MA   Kim Shinhye S   Henry Bonnie B   Hoang Linda M N LMN   Sadarangani Manish M   Jassem Agatha N AN   Krajden Mel M  

The Journal of infectious diseases 20220801 1


<h4>Background</h4>In British Columbia, Canada, most adults 50-69 years old became eligible for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in April 2021, with chimpanzee adenoviral vectored vaccine (ChAdOx1) restricted to ≥55-year-olds and second doses deferred ≥6 weeks to optimize single-dose coverage.<h4>Methods</h4>Among adults 50-69 years old, single-dose messenger RNA (mRNA) and ChAdOx1 vaccine effectiveness (VE) against SARS-CoV-2 infection and hospitalization, in  ...[more]

Similar Datasets

| S-EPMC8406884 | biostudies-literature
| S-EPMC9047244 | biostudies-literature
| S-EPMC3310194 | biostudies-literature
| S-EPMC9047203 | biostudies-literature
| S-EPMC3378608 | biostudies-other
| S-EPMC9864904 | biostudies-literature
| S-EPMC6969542 | biostudies-literature
| S-EPMC9880035 | biostudies-literature
| S-EPMC5541159 | biostudies-literature
| S-EPMC10734183 | biostudies-literature